Fulcrum Therapeutics Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Fulcrum Therapeutics Inc 's ROA in the first quarter of 2026?
Fulcrum Therapeutics Inc recorded a cumulative net loss of $-76 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -26.37%.

However, within the Healthcare sector 394 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 3526, from total ROA ranking in the fourth quarter of 2025 at 4111.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	43.23 %	40.49 %	-23.2 %	-22.49 %	4.09 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-76	-75	-71	-73	-1
Return On Assets (TTM)	-26.37 %	-28.52 %	-30.12 %	-29.02 %	-0.19 %
FULC's Total Ranking	# 3526	# 4111	# 3757	# 3795	# 2611
Total Assets (TTM) in million	347	366	214	228	242
Seq. Total Assets Change	-5.33 %	71.13 %	-5.98 %	-5.97 %	-7.14 %
Seq. Net Income Change	-	-	-	-	-

FULC's 5 Years Annual ROA >> Back to FULC Management Effectiveness >> Compare FULC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 150
Sector	# 395
Overall	# 3499

Return On Assets Statistics
High	Average	Low
-0.19 %	-32.01 %	-55.38 %
		(Dec 31 2020)

Financial Statements
Fulcrum Therapeutics Inc 's Assets	$ 347 million	FULC's Balance sheet
Fulcrum Therapeutics Inc 's Income	$ -19 million	Quarterly FULC's Income Statement
FULC's Income by Division		See FULC's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	40.49 %	1.68 %	13.25 %	-3.65 %	82.3 %
Total Assets in million	366	261	256	226	235
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-75	-10	-97	-110	-81
Annual Return On Assets	-20.44 %	-3.73 %	-37.96 %	-48.52 %	-34.4 %

FULC's 5 Years Annual ROA >> Back to FULC Management Effectiveness >> Compare FULC ROA to its Competitors

More Return On Assets Ratios
FULC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FULC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FULC's Competitors
Subscribers only: Roa for Fulcrum Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for FULC's Customers

You may also want to know
FULC's Roi	FULC's Inventory Turnover Ratio	FULC's Growth Rates	FULC's Dividend Comparisons
	FULC's Profitability Ratios	FULC's Asset Turnover Ratio	FULC's Dividend Growth
FULC's Roe	FULC's Valuation Ratios	FULC's Financial Strength Ratios	FULC's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-08-30T14:59:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.